---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-005171"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2023-01-10T23:59:59+00:00"
generated_at: "2026-06-20T17:13:44.451091+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kymera reports ~$560M cash, 2023 pipeline goals including KT-474 Phase 2 start with Sanofi

## Summary
- Preliminary cash, cash equivalents and investments of ~$560M as of Dec 31, 2022, runway into H2 2025.
- KT-474 (IRAK4 degrader) Phase 2 trials in HS and AD to initiate in 2023 in collaboration with Sanofi.
- KT-333 (STAT3) Phase 1 dose escalation ongoing; 66% mean STAT3 degradation in PBMC at first dose level.
- KT-413 (IRAKIMiD) Phase 1 completed two dose levels; dose-dependent degradation of IRAK4, Ikaros, Aiolos; no DLTs.
- KT-253 (MDM2) IND cleared; Phase 1a to start Q1 2023 in solid tumors and hematological malignancies.

## SEC filing metadata
- accession: 0001193125-23-005171
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2023-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312523005171/0001193125-23-005171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312523005171/d447672d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-005171
- JSON: https://secwatch.observer/filing/0001193125-23-005171.json
- Plain text: https://secwatch.observer/filing/0001193125-23-005171.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.